
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
A scientific panel recommended against smallpox vaccinations for the general public because of possible side effects vaccinations could cause, both to the inoculators and the recipients of the vaccine.